BEAM THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.02 USD | +12.98% |
|
+5.44% | -11.76% |
| May. 07 | Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates | MT |
| May. 07 | Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4,611 | 5,327 | 2,692 | 2,159 | 1,678 | - | - |
| Enterprise Value (EV) 1 | 4,318 | 4,367 | 1,613 | 969.4 | 891.3 | 1,302 | 1,678 |
| P/E ratio | -19.5 x | -13.8 x | -9.47 x | -15.8 x | -4.5 x | -4.5 x | -4.51 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 192,105 x | 103 x | 44.2 x | 5.72 x | 33.5 x | 32.2 x | 28.2 x |
| EV / Revenue | 179,928 x | 84.2 x | 26.5 x | 2.57 x | 17.8 x | 25 x | 28.2 x |
| EV / EBITDA | - | -11.3 x | -4.97 x | -6.2 x | -2.2 x | -3 x | -3.67 x |
| EV / FCF | -38.5 x | -38.6 x | -61.1 x | -5.3 x | -2.33 x | -3.5 x | -5.15 x |
| FCF Yield | -2.6% | -2.59% | -1.64% | -18.9% | -42.9% | -28.5% | -19.4% |
| Price to Book | 15.5 x | 6.19 x | 3.66 x | 2.14 x | 2 x | 2.4 x | - |
| Nbr of stocks (in thousands) | 56,474 | 66,849 | 68,821 | 79,326 | 78,909 | - | - |
| Reference price 2 | 81.64 | 79.69 | 39.11 | 27.22 | 21.26 | 21.26 | 21.26 |
| Announcement Date | 3/15/21 | 2/28/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.018 | 0.024 | 51.84 | 60.92 | 377.7 | 50.11 | 52.04 | 59.41 |
| EBITDA 1 | - | - | -385 | -324.3 | -156.5 | -405.1 | -433.4 | -457.3 |
| EBIT 1 | -75.15 | -132.8 | -392.5 | -338.5 | -176.5 | -423.3 | -449.6 | -482.6 |
| Operating Margin | -417,522.22% | -553,166.67% | -757.01% | -555.61% | -46.73% | -844.72% | -864.1% | -812.44% |
| Earnings before Tax (EBT) 1 | -78.33 | -194.6 | -370.6 | -260.2 | -131.2 | -401.5 | -430.9 | -461.2 |
| Net income 1 | -91.04 | -195.9 | -370.6 | -289.1 | -132.5 | -402.1 | -432.1 | -454.4 |
| Net margin | -505,777.78% | -816,120.83% | -714.91% | -474.54% | -35.09% | -802.45% | -830.38% | -764.97% |
| EPS 2 | -2.489 | -4.190 | -5.770 | -4.130 | -1.720 | -4.728 | -4.725 | -4.712 |
| Free Cash Flow 1 | -84.52 | -112.1 | -113.1 | -26.42 | -182.9 | -382.6 | -371.5 | -326 |
| FCF margin | -469,561.11% | -467,075% | -218.11% | -43.37% | -48.43% | -763.43% | -713.96% | -548.83% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/15/21 | 2/28/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 51.07 | 8.432 | 16.65 | 15.8 | 20.04 | 24.21 | 20.12 | 17.19 | 316.2 | 7.41 | 12.41 | 12.87 | 13.73 | 10 | 10 |
| EBITDA 1 | -60.85 | -72.91 | - | -87.83 | -85.04 | - | -97.33 | -103.1 | 138.2 | -98.7 | -90.71 | -97.34 | -102.9 | - | - |
| EBIT 1 | -63.48 | -76.22 | -81.97 | -91.3 | -88.98 | -98.93 | -102.1 | -108.3 | 132.9 | -104.1 | -101.8 | -103.7 | -117.9 | -115 | -120 |
| Operating Margin | -124.31% | -904% | -492.23% | -577.9% | -444.1% | -408.66% | -507.79% | -629.72% | 42.02% | -1,405.29% | -819.92% | -806.2% | -858.88% | -1,150% | -1,200% |
| Earnings before Tax (EBT) 1 | -64.71 | -69.21 | -71.95 | -81.66 | -37.35 | -96.46 | -82.78 | -96.09 | 144.2 | -98.67 | -94.02 | -96.87 | -112.1 | -114 | -119 |
| Net income 1 | -64.71 | -69.21 | -71.95 | -109.6 | -38.35 | -96.46 | -82.78 | -96.09 | 142.8 | -98.67 | -94.8 | -97.37 | -111.4 | -114 | -119 |
| Net margin | -126.71% | -820.85% | -432.08% | -693.56% | -191.39% | -398.46% | -411.49% | -558.88% | 45.16% | -1,331.57% | -763.63% | -756.59% | -811.39% | -1,140% | -1,190% |
| EPS 2 | -0.9500 | -1.010 | -1.020 | -1.560 | -0.5400 | -1.330 | -1.080 | -1.220 | 1.730 | -1.210 | -1.129 | -1.147 | -1.260 | -1.172 | -1.185 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 5/9/22 | 8/9/22 | 11/7/22 | 2/28/23 | 5/10/23 | 8/8/23 | 11/8/23 | 2/27/24 | 5/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 292 | 960 | 1,078 | 1,190 | 786 | 376 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -84.5 | -112 | -113 | -26.4 | -183 | -383 | -372 | -326 |
| ROE (net income / shareholders' equity) | - | -881% | -69.1% | -37.1% | -15.5% | -50% | -68.6% | -80.3% |
| ROA (Net income/ Total Assets) | -56.4% | -64.5% | -38.5% | -20.5% | -11.7% | -30.3% | -35.8% | - |
| Assets 1 | 161.6 | 303.9 | 963.1 | 1,408 | 1,134 | 1,326 | 1,208 | - |
| Book Value Per Share 2 | -3.920 | 5.250 | 12.90 | 10.70 | 12.70 | 10.70 | 8.870 | - |
| Cash Flow per Share 2 | - | - | -1.030 | 0.3200 | -1.930 | -3.830 | -3.580 | - |
| Capex 1 | 12.5 | 16.4 | 46.8 | 49 | 33.7 | 29.7 | 31.2 | 30.6 |
| Capex / Sales | 69,544.44% | 68,154.17% | 90.29% | 80.35% | 8.93% | 59.2% | 59.96% | 51.57% |
| Announcement Date | 3/30/20 | 3/15/21 | 2/28/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
24.02
USD
Average target price
48.38
USD
Spread / Average Target
+101.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.76% | 1.68B | |
| +26.37% | 44.96B | |
| -1.01% | 42.65B | |
| +46.00% | 41.85B | |
| -5.31% | 29.04B | |
| +9.34% | 26.08B | |
| -21.69% | 19.03B | |
| +6.23% | 12.75B | |
| +26.99% | 12.06B | |
| -3.38% | 11.75B |
- Stock Market
- Equities
- BEAM Stock
- Financials Beam Therapeutics Inc.